A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population

Vaccine

Volumn 27, Issue 16, 2009, Pages 2251-2257

  Lee, Bruce Y ^a,b   Ercius, Anna K ^a,b   Smith, Kenneth J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Computer simulation; Influenza vaccine adjuvant; Older adults

Indexed keywords

INFLUENZA VACCINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; COMPUTER SIMULATION; DRUG COST; DRUG EFFICACY; ECONOMICS; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFLUENZA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEASONAL VARIATION; SOCIOECONOMICS;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; AGING; COMPUTER SIMULATION; HUMANS; INFLUENZA VACCINES;

EID: 61849122853     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.024     Document Type: Article

References (50)

1. Fleming D.M., Watson J.M., Nicholas S., Smith G.E., and Swan A.V. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989-90 using a general practice database. Epidemiol Infect 115 December (3) (1995) 581-589
2. Govaert T.M., Thijs C.T., Masurel N., Sprenger M.J., Dinant G.J., and Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 272 December (21) (1994) 1661-1665
3. Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21 May (16) (2003) 1769-1775
4. Fedson D.S., Wajda A., Nicol J.P., Hammond G.W., Kaiser D.L., and Roos L.L. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 270 October (16) (1993) 1956-1961
5. Nichol K.L., Wuorenma J., and von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 158 September (16) (1998) 1769-1776
6. Nicholson K.G., Wood J.M., and Zambon M. Influenza. Lancet 362 November (9397) (2003) 1733-1745
7. Nordin J., Mullooly J., Poblete S., Strikas R., Petrucci R., Wei F., et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 184 September (6) (2001) 665-670
8. Treanor J.J., Campbell J.D., Brady R.C., Keitel W.A., Drame M., Jain V.K., and Innis B.L. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccine 1 November-December (6) (2005) 239-244
9. McElhaney J.E. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 23 July (Suppl. 1) (2005) S10-25
10. Murasko D.M., Bernstein E.D., Gardner E.M., Gross P., Munk G., Dran S., and Abrutyn E. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 37 January-March (2-3) (2002) 427-439
11. Rivetti D., Jefferson T., Thomas R., Rudin M., Rivetti A., Di Pietrantonj C., and Demicheli V. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 3 (2006) CD004876
12. Gold M.R., Franks P., McCoy K.I., and Fryback D.G. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 36 June (6) (1998) 778-792
13. Garrett N., and Martini E.M. The boomers are coming: a total cost of care model of the impact of population aging on the cost of chronic conditions in the United States. Dis Manag 10 April (2) (2007) 51-60
14. Martini E.M., Garrett N., Lindquist T., and Isham G.J. The boomers are coming: a total cost of care model of the impact of population aging on health care costs in the United States by Major Practice Category. Health Serv Res 42 February (1 Pt 1) (2007) 201-218
15. Yap F.H., Ho P.L., Lam K.F., Chan P.K., Cheng Y.H., and Peiris J.S. Excess hospital admissions for pneumonia, chronic obstructive pulmonary disease, and heart failure during influenza seasons in Hong Kong. J Med Virol 73 August (4) (2004) 617-623
16. Nguyen-Van-Tam J.S., Brockway C.R., Pearson J.C., Hayward A.C., and Fleming D.M. Excess hospital admissions for pneumonia and influenza in persons > or = 65 years associated with influenza epidemics in three English health districts: 1987-95. Epidemiol Infect 126 February (1) (2001) 71-79
17. Palese P. Making better influenza virus vaccines?. Emerg Infect Dis 12 January (1) (2006) 61-65
18. Baldo V., Baldovin T., Floreani A., Carraro A.M., and Trivello R. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 25 May (20) (2007) 3955-3961
19. Atmar R.L., Keitel W.A., Patel S.M., Katz J.M., She D., El Sahly H., et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43 November (9) (2006) 1135-1142
20. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 September (9540) (2006) 991-997
21. Iob A., Brianti G., Zamparo E., and Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 133 August (4) (2005) 687-693
22. Sambhara S., Kurichh A., Miranda R., Tumpey T., Rowe T., Renshaw M., et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 211 August (2) (2001) 143-153
23. Fritz J.H., Brunner S., Birnstiel M.L., Buschle M., Gabain A., Mattner F., and Zauner W. The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens. Vaccine 22 September (25-26) (2004) 3274-3284
24. Ichinohe T., Watanabe I., Ito S., Fujii H., Moriyama M., Tamura S., et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79 March (5) (2005) 2910-2919
25. Kohut M.L., Cooper M.M., Nickolaus M.S., Russell D.R., and Cunnick J.E. Exercise and psychosocial factors modulate immunity to influenza vaccine in elderly individuals. J Gerontol A Biol Sci Med Sci 57 September (9) (2002) M557-M562
26. Keitel W.A., Atmar R.L., Cate T.R., Petersen N.J., Greenberg S.B., Ruben F., and Couch R.B. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 166 May (10) (2006) 1121-1127
27. Hamazaki K., Sawazaki S., Itomura M., Huan M., Shibahara N., Kawakita T., et al. No effect of a traditional Chinese medicine, Hochu-ekki-to, on antibody titer after influenza vaccination in man: a randomized, placebo-controlled, double-blind trial. Phytomedicine 14 January (1) (2007) 11-14
28. Gill H.S., Rutherfurd K.J., and Cross M.L. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. J Clin Immunol 21 July (4) (2001) 264-271
29. Choi C. Bacterial meningitis in aging adults. Clin Infect Dis 33 October (8) (2001) 1380-1385
30. McElhaney J.E. Overcoming the challenges of immunosenescence in the prevention of acute respiratory illness in older people. Conn Med 67 September (8) (2003) 469-474
31. PDR Staff (ed.) Red Book, 2007 ed. Montvale, NJ: Thompson Healthcare Inc., 2007.
32. Sudafed non-drowsy maximum strength nasal decongestant tablets [cited 2008 January 25]. Available from: http://www.drugstore.com/products/prod.asp?pid=11509&catid=382.
33. Centers for Medicare & Medicaid Services; 2008 [cited 2008 February 4]. Available from: http://www.cms.hhs.gov/.
34. National Compensation Survey: occupational wages in the United States, June 2006. Labor USDo ed., 2007.
35. Levit K, Ryan K, Elixhauser A, Stranges E, Kassed C, Coffey R. HCUP facts and figures: Statistics on hospital-based care in the United States in 2005. Accessed at www.hcup-us.ahrq.gov/reports.jsp on 5 March 2008.
36. Smith K.J., and Roberts M.S. Cost-effectiveness of newer treatment strategies for influenza. Am J Med 113 September (4) (2002) 300-307
37. Advisory Committee on Immunization Practices, Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48(April (RR-4)):1-28.
38. Winquist AG, Fukuda K, Bridges CB, Cox NJ. Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR Recomm Rep 1999;48(December (RR-14)):1-9.
39. Gubareva L.V., Kaiser L., and Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet 355 March (9206) (2000) 827-835
40. Hayden F.G., Osterhaus A.D., Treanor J.J., Fleming D.M., Aoki F.Y., Nicholson K.G., et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 337 September (13) (1997) 874-880
41. Jefferson T.O., Demicheli V., Deeks J.J., and Rivetti D. Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst Rev 2 (2000) CD001169
42. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283 February (8) (2000) 1016-1024
43. Sackett D.L., and Torrance G.W. The utility of different health states as perceived by the general public. J Chronic Dis 31 11 (1978) 697-704
44. Wan He, Manisha Sengupta, Victoria A, Velkoff, Kimberly A. DeBarros. Bureau USC. 65+ in the United States: 2005 Current Population Reports. US Census Bureau, Current Population Reports. 2005;P23-209(December):1-243.
45. Govaert T.M., Dinant G.J., Aretz K., Masurel N., Sprenger M.J., and Knottnerus J.A. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 307 October (6910) (1993) 988-990
46. Jefferson T.O., Rivetti D., Di Pietrantonj C., Rivetti A., and Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2 (2007) CD001269
47. Hetzel L, Smith A. The 65 Years and Over Population: 2000. Washington, DC: U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau; October 2001.
48. Wilmoth JR, Shkolnikov V. Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). Available at www.mortality.org or www.humanmortality.de (data downloaded on 21 January 2008).
49. U.S. Department of Health and Human Services, National Center for Health Statistics. National Health Interview Survey, 1997-2006. U.S. Dept. of Health and Human Services, National Center for Health Statistics, Hyattsville, MD, 2007.
50. Monto A.S., Hornbuckle K., and Ohmit S.E. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 154 July (2) (2001) 155-160